Phospholipid storage in the myocardium of a unique Japanese case of idiopathic cardiomyopathy

Clinica Chimica Acta

Volumn 372, Issue 1-2, 2006, Pages 154-157

  Kawashima, Ikuo ^a   Takeuchi, Ichiro ^b   Ohsawa, Mai ^a,c   Kotani, Masaharu ^a   Tajima, Youichi ^a   Inomata, Takayuki ^b   Izumi, Tohru ^b   Sakuraba, Hitoshi ^a  

^a TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^b KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

Cardiomyopathy; Fabry disease; Glycolipid; Inclusion body; Phospholipids

Indexed keywords

ALPHA GALACTOSIDASE; GANGLIOSIDE; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLINOSITOL; PHOSPHOLIPID;

ADULT; ARTICLE; AUTOPSY; CARDIAC PATIENT; CARDIOMYOPATHY; CASE REPORT; CELL INCLUSION; CHEMICAL ANALYSIS; DIFFERENTIAL DIAGNOSIS; ELECTRON MICROSCOPE; ENZYME ACTIVITY; FABRY DISEASE; HEART; HEART MUSCLE; HEART MUSCLE CELL; HUMAN; LAMELLAR BODY; LIPID ANALYSIS; LIPID STORAGE; LIPIDOSIS; MALE; MYOCARDIAL DISEASE; PATHOGENESIS; PRIORITY JOURNAL; ULTRASTRUCTURE;

ALPHA-GALACTOSIDASE; AUTOPSY; CARDIOMYOPATHIES; CHROMATOGRAPHY, THIN LAYER; HUMANS; MALE; MIDDLE AGED; PHOSPHOLIPIDS;

EID: 33747846902     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2006.04.009     Document Type: Article

References (20)

1. In: Glew R.H., and Peters S.P. (Eds). Practical enzymology of the sphingolipidosis (1977), Alan R. Liss, New York
2. Gonzalez-Noriega A., Grubb J.H., Talkad V., and Sly W.S. Chloroquine inhibits lysosomal enzyme pinocytosis and enhances lysosomal enzyme secretion by impairing receptor recycling. J Cell Biol 85 (1980) 839-852
3. Desnick R.J., Ioannou Y.A., and Eng C.M. α-Galactosidase a deficiency: Fabry disease. In: Scriver C.R., Beaudet A.L., Sly W.S., and Valle D. (Eds). The metabolic and molecular bases of inherited disease. 8th ed. (2001), McGraw-Hill, New York 3733-3774
4. Elleder M., Bradova V., Smid F., et al. Cardiocyte storage and hypertrophy as a sole manifestation of Fabry's disease. Report on a case simulating hypertrophic non-obstructive cardiomyopathy. Virchows Arch, A Pathol Anat Histopathol 417 (1990) 449-455
5. von Scheidt W., Eng C.M., Fitzmaurice T.F., et al. An atypical variant of Fabry's disease with manifestations confined to the myocardium. N Engl J Med 324 (1991) 395-399
6. Nakao S., Takeoka T., Maeda M., et al. An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med 333 (1995) 288-293
7. Takata T., Okumiya T., Hayashibe H., et al. Screening and detection of gene mutations in Japanese patients with Fabry disease by non-radioactive single-stranded conformation polymorphism analysis. Brain Dev 19 (1997) 111-116
8. Mayes J.S., Scheerer J.B., Sifers R.N., and Donaldson M.L. Differential assay for lysosomal α-galactosidase in human tissues and its application to Fabry's disease. Clin Chim Acta 112 (1981) 247-251
9. Svennerholm L., and Fredman P. A procedure for the quantitative isolation of brain gangliosides. Biochim Biophys Acta 617 (1980) 97-109
10. Rocquelin G., Guenot L., Astorg P.O., and David M. Phospholipid content and fatty acid composition of human heart. Lipids 24 (1989) 775-780
11. Kotani M., Kawashima I., Ozawa H., Ogura K., Ariga T., and Tai T. Generation of one set of murine monoclonal antibodies specific for globo-series glycolipids: evidence for differential distribution of the glycolipids in rat small intestine. Arch Biochem Biophys 310 (1994) 89-96
12. Ledeen R.W., and Yu R.K. Gangliosides: structure, isolation, and analysis. Methods Enzymol 83 (1982) 139-191
13. Desnick R.J., Brady R., Barranger J., et al. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 138 (2003) 338-346
14. Van Bambeke F., Gerbaux C., Michot J.-M., d'Yvoire M.B., Montenez J.-P., and Tulkens P.M. Lysosomal alterations induced in cultured rat fibroblasts by long-term exposure to low concentrations of azithromycin. J Antimicrob Chemother 42 (1998) 761-767
15. Philippart M., Anderson M., Kamp K., Crandall B.R., and Brown W.J. Mucolipidosis IV: a phospholipidosis. Trans Am Soc Neurochem 11 (1980) 72
16. Bargal R., and Bach G. Phospholipids accumulation in mucolipidosis IV cultured fibroblasts. J Inherit Metab Dis 11 (1988) 144-150
17. Bach G., Cohen M.M., and Kohn G. Abnormal ganglioside accumulation in cultured fibroblasts from patients with mucolipidosis IV. Biochem Biophys Res Commun 66 (1975) 1483-1490
18. Caimi L., Tettamanti G., Berra B., et al. Mucolipidosis IV, a sialolipidosis due to ganglioside sialidase deficiency. J Inherit Metab Dis 5 (1982) 218-224
19. Sun M., Goldin E., Stahl S., et al. Mucolipidosis type IV is caused by mutations in a gene encoding a novel transient receptor potential channel. Hum Mol Genet 9 (2000) 2471-2478
20. Raychowdhury M.K., González-Perrett S., Montalbetti N., et al. Molecular pathophysiology of mucolipidosis type IV: pH dysregulation of the mucolipin-1 cation channel. Hum Mol Genet 13 (2004) 617-627